Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7U5QJ)

Drug Name
Cinnarizine Drug Info
Synonyms
Aplactan; Aplexal; Apotomin; Artate; Carecin; Cerebolan; Cinaperazine; Cinarizina; Cinarizine; Cinazyn; Cinnacet; Cinnageron; Cinnarizinum; Corathiem; Denapol; Dimitron; Dimitronal; Eglen; Folcodal; Giganten; Glanil; Hilactan; Ixertol; Katoseran; Labyrin; Lazeta; Libotasin; Marisan; Midronal; Mitronal; Olamin; Processine; Sedatromin; Senoger; Sepan; Siptazin; Spaderizine; Stugeron; Stutgeron; Stutgin; Toliman; Votegol; Zepamol; Cinnarizine Stugeron; C 5270; MD 516; R 1575; R 516; Cero-Aterin; Cinarizina [INN-Spanish]; Cinnarizinum [INN-Latin]; R-516; Stugeron (TN); Stunarone (TN); Cinnarizine (JAN/USAN/INN); Cinnarizine [USAN:INN:BAN:JAN]; N-Benzhydryl-N'-cinnamylpiperazine; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; 1-Benzhydryl-4-cinnamylpiperazin; 1-Cinnamyl-4-(diphenylmethyl)piperazine; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; 1-trans-Cinnamyl-4-diphenylmethylpiperazine
Indication
Disease Entry ICD 11 Status REF
Meniere disease AB31.0 Approved [1]
Nausea MD90 Approved [2]
Vertigo meniere disease AB31.0 Approved [3]
Therapeutic Class
Antiallergic Agents
Cross-matching ID
PubChem CID
1547484
ChEBI ID
CHEBI:31403
CAS Number
CAS 16699-20-0
TTD Drug ID
DM7U5QJ
INTEDE Drug ID
DR0329

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Phase 4 [5]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Phase 4 [6]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Phase 4 [6]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Phase 4 [6]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Phase 4 [7]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Phase 4 [6]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Histamine H1 receptor (H1R) DTT HRH1 5.972 5.7 5.816 6.002
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 10.644 6.631 6.598 6.937
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 10.036 5.779 6.508 6.481
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 3.307 5.005 3.921 5.327
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 11.76 5.931 6.164 9.423
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Meniere disease
ICD Disease Classification AB31.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.32E-01 4.39E-02 4.30E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 8.99E-01 4.59E-03 2.19E-02
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.46E-01 -6.63E-03 -4.49E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Association of cinnarizine and betahistine in prophylactic therapy for Mnire's disease with and without migraine. Acta Otorhinolaryngol Ital. 2014 Oct;34(5):349-53.
2 Cinnarizine: A Contemporary Review. Indian J Otolaryngol Head Neck Surg. 2019 Nov;71(Suppl 2):1060-1068.
3 Drug information of Cinnarizine, 2008. eduDrugs.
4 Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
5 Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
6 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
7 Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94.